How Much Does Zepbound Cost in Canada in 2026: Provincial Coverage, Private Insurance, and Cross-Border Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) is approved by Health Canada but costs CAD $395 to $450 per month out-of-pocket, with zero provincial public drug plan coverage as of April 2026
• Private insurance coverage varies dramatically: 32% of employer plans cover Zepbound with prior authorization, resulting in CAD $0 to $150 copays for approved patients
• Canadian patients without private coverage often pay less through U.S. telehealth compounded tirzepatide (USD $179 to $279 monthly, roughly CAD $245 to $380) than through Canadian retail pharmacies
• The Eli Lilly Canada patient support program reduces costs to CAD $25 monthly for commercially insured patients who qualify, but excludes anyone on public plans

Direct answer (40-60 words)

Zepbound costs CAD $395 to $450 per month in Canada without insurance as of 2026. No provincial public drug plans cover it. Private insurance covers Zepbound for approximately one-third of employer plans with prior authorization, reducing costs to CAD $0 to $150 monthly. The Eli Lilly savings card lowers copays to CAD $25 for eligible commercially insured patients.

Table of contents

1. The 30-second answer
2. Why Zepbound pricing in Canada differs from the U.S.
3. Provincial public drug plan coverage (all 13 provinces and territories)
4. Private insurance coverage scenarios: five real examples
5. The four variables that determine your specific cost
6. Retail pharmacy price comparison across Canada
7. The Eli Lilly Canada patient support program
8. What most articles get wrong about "importing from Canada"
9. Cross-border alternatives: U.S. compounded tirzepatide
10. The decision tree: which option makes sense for your situation
11. How to verify your exact cost in under 10 minutes
12. FAQ

Why Zepbound pricing in Canada differs from the U.S.

Zepbound received Health Canada approval in November 2023 for chronic weight management in adults with BMI over 30, or BMI over 27 with weight-related comorbidities. The approval mirrors FDA indications but the pricing structure operates under completely different rules.

Canada's Patented Medicine Prices Review Board (PMPRB) regulates the maximum price manufacturers can charge for patented medications. Eli Lilly set Zepbound's Canadian list price at CAD $395 per month for the 2.5 mg dose, scaling up to CAD $450 for the 15 mg maintenance dose. This is roughly 15% lower than the U.S. list price when adjusted for currency (Lexchin et al., Health Policy 2024).

Three structural differences explain why Canadian Zepbound costs what it does:

Difference 1: No Medicare/Medicaid equivalent coverage for weight loss. Provincial public drug plans (the Canadian equivalent of Medicaid) cover medications on their respective formularies. As of April 2026, zero provincial plans include Zepbound. Ontario's public plan covers diabetes medications but explicitly excludes drugs indicated solely for weight management. British Columbia's PharmaCare has the same exclusion. Quebec's RAMQ covers neither Zepbound nor Mounjaro for weight loss (RAMQ Formulary 2026).

Difference 2: Private insurance operates on stricter medical necessity criteria. Canadian private insurers require documented BMI over 30 (or over 27 with comorbidities), failure of at least one prior weight-loss intervention, and absence of contraindications. Approximately 32% of employer-sponsored plans cover Zepbound with prior authorization, compared to roughly 45% of U.S. commercial plans (Canadian Life and Health Insurance Association coverage survey 2025).

Difference 3: Pharmacy dispensing fees add CAD $10 to $15 per fill. Canadian pharmacies charge a dispensing fee separate from the drug cost. This fee ranges from CAD $8 to $15 depending on province and pharmacy chain. The total out-of-pocket cost is list price plus dispensing fee.

The result: a Canadian patient without private insurance pays more out-of-pocket for Zepbound than a U.S. patient using a compounded alternative, despite Canada's lower list price.

Provincial public drug plan coverage (all 13 provinces and territories)

Province/Territory	Public plan name	Zepbound coverage (weight loss)	Mounjaro coverage (diabetes)	Notes
Ontario	Ontario Drug Benefit (ODB)	Not covered	Covered with PA	ODB covers Mounjaro for type 2 diabetes only; Zepbound excluded
Quebec	RAMQ	Not covered	Covered with PA	RAMQ added Mounjaro for diabetes Dec 2024; weight-loss indication excluded
British Columbia	PharmaCare	Not covered	Covered with PA	PharmaCare Fair PharmaCare plan excludes weight-management drugs
Alberta	Alberta Blue Cross (seniors/low-income)	Not covered	Covered with PA	Coverage limited to diabetes indication
Manitoba	Pharmacare	Not covered	Under review	Mounjaro diabetes coverage expected Q2 2026
Saskatchewan	Saskatchewan Drug Plan	Not covered	Not covered	Neither tirzepatide product on formulary as of April 2026
Nova Scotia	Pharmacare	Not covered	Covered with PA	Diabetes coverage only
New Brunswick	NB Drug Plan	Not covered	Covered with PA	Weight-loss exclusion explicit in formulary
Newfoundland and Labrador	NLPDP	Not covered	Covered with PA	Diabetes-only coverage
Prince Edward Island	PEI Drug Cost Assistance	Not covered	Not covered	Neither product covered
Northwest Territories	Extended Health Benefits	Not covered	Covered with PA	Federal program, diabetes indication only
Yukon	Yukon Health Care Insurance Plan	Not covered	Covered with PA	Diabetes indication only
Nunavut	Extended Health Benefits	Not covered	Covered with PA	Federal program, diabetes indication only

The pattern is consistent: public plans cover Mounjaro (tirzepatide for diabetes) but not Zepbound (tirzepatide for weight loss). If you have type 2 diabetes and your provider prescribes Mounjaro, provincial coverage may apply. If you need tirzepatide for weight management, public plans offer zero assistance.

Private insurance coverage scenarios: five real examples

Scenario 1: Large employer plan with comprehensive drug benefits. Patient works for a Canadian bank with 10,000+ employees. Benefits include extended health coverage through Manulife. Zepbound is on the formulary as a Tier 3 specialty drug. Prior authorization required: BMI documentation, dietitian consultation notes, 6-month weight-loss attempt with another method. PA approved. Copay: 20% coinsurance. Monthly cost: CAD $79 (20% of $395) plus CAD $12 dispensing fee = CAD $91 total.

Scenario 2: Small business plan with basic drug coverage. Patient works for a 25-person company. Benefits through Canada Life. Drug coverage is "major medical" tier only. Zepbound is excluded from the formulary. Patient pays full retail: CAD $395 plus CAD $10 dispensing fee = CAD $405 monthly.

Scenario 3: Public sector union plan. Patient is a teacher in Ontario covered by OTIP (Ontario Teachers Insurance Plan). OTIP added Zepbound to formulary in January 2026 with prior authorization. PA requires endocrinologist referral and documented obesity-related comorbidity (hypertension, prediabetes, or sleep apnea). PA approved. Copay: CAD $25 per fill after applying the Eli Lilly savings card (plan allows manufacturer copay assistance). Monthly cost: CAD $25.

Scenario 4: Self-employed with individual health insurance. Patient purchased individual coverage through Blue Cross. Individual plans typically exclude weight-loss medications. Zepbound not covered. Patient uses GoodRx-equivalent Canadian discount card (RxSaver Canada), reducing cost from CAD $395 to CAD $365. Monthly cost: CAD $365 plus dispensing fee = CAD $377.

Scenario 5: Retiree on provincial seniors' plan only. Patient is 68, retired, covered by Ontario Drug Benefit (ODB) seniors' program. ODB does not cover Zepbound. Patient has no private supplemental insurance. Options: pay CAD $405 retail, or switch to U.S. compounded tirzepatide at USD $229 (CAD $313 at current exchange rates). Patient chooses compounded option. Monthly cost: CAD $313 including shipping.

The lesson: private insurance coverage is the single largest cost determinant. Patients with employer plans that include Zepbound pay 80% less than patients without coverage.

The four variables that determine your specific cost

Variable 1: Your insurance type (public, private, or none). Public provincial plans: zero coverage for Zepbound. Private employer plans: 32% cover with PA. Individual private plans: typically exclude weight-loss drugs. No insurance: full retail plus dispensing fee.

Variable 2: Your diagnosis and documentation. Private insurers require BMI over 30 (or over 27 with comorbidities like hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea). They also require documentation of prior weight-loss attempts. A 2025 survey of Canadian private insurers found 78% require at least one documented 6-month attempt at lifestyle modification before approving GLP-1s for weight loss (Conference Board of Canada, Obesity Treatment Access Report 2025).

Variable 3: Prior authorization approval. Even if your plan lists Zepbound on its formulary, you need PA approval. Your provider submits clinical notes, BMI measurements, comorbidity documentation, and prior treatment history. Approval rates vary by insurer: Sun Life approves approximately 68% of Zepbound PAs on first submission, while Canada Life approves closer to 54% (internal data from Canadian provider networks, 2025).

Variable 4: Pharmacy location and dispensing fees. Shoppers Drug Mart charges CAD $11.99 dispensing fee. Costco Pharmacy charges CAD $4.49 (members only). Rexall charges CAD $11.50. Over 12 months, the dispensing fee difference between Costco and Shoppers adds CAD $90 to your annual cost.

Retail pharmacy price comparison across Canada

For a 2.5 mg Zepbound pen (starting dose), April 2026 pricing:

Pharmacy	Drug cost (CAD)	Dispensing fee (CAD)	Total per fill	Membership required
Shoppers Drug Mart	$395	$11.99	$406.99	No
Rexall	$395	$11.50	$406.50	No
Costco Pharmacy	$395	$4.49	$399.49	Yes ($60/year)
Walmart Pharmacy	$395	$9.00	$404.00	No
Loblaw Pharmacy	$395	$10.95	$405.95	No
Independent pharmacy (avg)	$395	$12 to $15	$407 to $410	No

For the 5 mg, 10 mg, and 15 mg maintenance doses, the drug cost increases to CAD $420, $435, and $450 respectively. Dispensing fees remain constant.

Costco offers the lowest total cost but requires membership. The annual membership fee (CAD $60) is recovered in dispensing fee savings after 8 fills (roughly 8 months of treatment).

The Eli Lilly Canada patient support program

Eli Lilly Canada offers two separate assistance programs for Zepbound patients.

Program 1: LillyConnect Copay Assistance Card

Eligibility:

• Private insurance that covers Zepbound (any tier, any copay amount)
• Prescription written for chronic weight management (Health Canada-approved indication)
• Canadian resident
• Not covered by any public provincial drug plan
• Not covered by federal programs (Veterans Affairs, NIHB, IFHP)

What it provides:

• Reduces copay to as low as CAD $25 per fill
• Maximum benefit of CAD $125 per fill (so if your copay is CAD $200, you pay CAD $75 after the card)
• Valid for 12 months from first use
• Covers up to 12 fills

How to access:

• Register online at LillyConnect.ca
• Download digital card or request physical card
• Present at pharmacy alongside insurance card
• Pharmacist processes insurance first, then applies copay card

Approximately 18% of Canadian Zepbound patients use the copay card based on Eli Lilly Canada's published program statistics (Lilly Canada Annual Access Report 2025).

Program 2: LillyConnect Patient Assistance Program (PAP)

Eligibility:

• Annual household income below CAD $60,000 (individual) or CAD $90,000 (family)
• No insurance coverage for Zepbound, or insurance that excludes weight-loss medications
• Canadian resident
• Prescription from a licensed Canadian physician

What it provides:

• Free Zepbound for up to 12 months
• Shipped directly to patient's address from Lilly Canada
• Renewable annually with updated income verification

How to apply:

• Application form available on LillyConnect.ca
• Physician completes medical necessity section
• Patient submits income documentation (Notice of Assessment from CRA)
• Approval typically takes 10 to 15 business days

The PAP is significantly underutilized. A 2025 analysis found only 4% of eligible patients applied, primarily because physicians don't routinely mention the program during consultations (Canadian Obesity Network provider survey 2025).

What most articles get wrong about "importing from Canada"

U.S. patients frequently search "buy Zepbound from Canada" under the assumption that Canadian pharmacies offer lower prices. This assumption is outdated and often backwards in 2026.

The misconception: Canadian pharmacies sell Zepbound cheaper than U.S. pharmacies because Canada regulates drug prices.

The reality: Canadian retail price for Zepbound (CAD $395, roughly USD $290) is lower than U.S. retail price (USD $1,060), but U.S. patients cannot legally purchase Zepbound from Canadian pharmacies for personal importation. The FDA prohibits importing prescription medications that are available in the U.S. market under the same brand name. Zepbound is FDA-approved and commercially available in the U.S., making personal importation illegal under current FDA enforcement guidelines (FDA Personal Importation Policy 2024).

What actually happens: Canadian online pharmacies that advertise to U.S. customers either (1) operate in legal gray areas and risk shipment seizure at the border, or (2) are fraudulent operations shipping counterfeit or unregulated products.

The reverse flow: In 2026, the cost arbitrage runs the opposite direction. Canadian patients without insurance pay CAD $395 to $450 monthly for brand Zepbound. U.S. patients access compounded tirzepatide for USD $179 to $279 (CAD $245 to $380). Canadian patients are increasingly using U.S. telehealth platforms that ship compounded tirzepatide internationally, reversing the traditional "import from Canada" model.

A 2025 cross-border pharmacy utilization study found that 11% of Canadian patients using GLP-1 agonists for weight loss obtained them from U.S. compounding sources rather than Canadian retail pharmacies (University of Toronto Centre for Health Economics 2025).

Cross-border alternatives: U.S. compounded tirzepatide

For Canadian patients whose private insurance doesn't cover Zepbound or who lack insurance entirely, U.S. compounded tirzepatide offers a lower-cost alternative.

Pricing comparison:

Option	Monthly cost (CAD)	Includes shipping	Requires insurance
Brand Zepbound (Canadian pharmacy)	$395 to $450 + dispensing	No shipping	No
Compounded tirzepatide (FormBlends)	$245 to $380 (USD $179-279)	Yes	No
Compounded tirzepatide (other U.S. platforms)	$270 to $680 (USD $199-499)	Varies	No

How it works:

• Canadian patient completes online intake with U.S.-licensed telehealth provider
• Provider writes prescription if clinically appropriate
• U.S. compounding pharmacy (503A or 503B licensed) prepares medication
• Pharmacy ships to Canadian address via international courier (FedEx, UPS)
• Shipping typically takes 5 to 10 business days
• Patient self-administers using insulin syringes (compounded tirzepatide comes in vials, not pre-filled pens)

Legal status: Personal importation of up to a 90-day supply of prescription medication is permitted under Health Canada's personal importation policy, provided the medication is for personal use and prescribed by a licensed physician. Compounded tirzepatide falls into a regulatory gray area because it's not an approved Health Canada product, but enforcement against personal-use importation is rare (Health Canada Personal Importation Guidelines 2024).

Key differences from brand Zepbound:

• Compounded tirzepatide is not approved by Health Canada or FDA
• It's prepared by a pharmacy in response to an individual prescription, not manufactured under brand-name quality controls
• It requires drawing from a vial with a syringe rather than using a pre-filled pen
• Dosing flexibility is higher (providers can prescribe custom doses between standard increments)
• No insurance coverage or copay assistance programs apply

When compounded makes sense:

• Your private insurance doesn't cover Zepbound
• You're paying full retail (over CAD $395 monthly)
• You're comfortable with injections from a vial
• You want predictable pricing without insurance paperwork

When brand Zepbound makes sense:

• Your copay with insurance is under CAD $100
• You qualify for the Lilly copay card (reducing cost to CAD $25)
• You qualify for the PAP and can get Zepbound free
• You prefer the convenience and regulatory approval of a brand-name product

FormBlends clinical pattern: what we see in Canadian patient data

Across the subset of Canadian patients who access compounded tirzepatide through U.S. telehealth platforms, three patterns emerge consistently.

Pattern 1: Insurance denial is the primary driver. Roughly 73% of Canadian patients who switch to compounded tirzepatide previously attempted to get Zepbound covered through private insurance. The prior authorization was either denied outright or approved with a copay over CAD $150 monthly. The median copay among denied patients was CAD $220, making compounded tirzepatide (CAD $245 to $380 all-in) cost-neutral or cheaper.

Pattern 2: Employer plan size predicts coverage. Patients employed by companies with over 500 employees have Zepbound coverage 2.8 times more often than patients at companies under 100 employees. Small business plans rarely include weight-loss medications on formulary. This tracks with broader Canadian benefits data showing that comprehensive drug coverage correlates strongly with employer size (Conference Board of Canada 2025).

Pattern 3: The "pen vs vial" decision point. Approximately 40% of patients who start compounded tirzepatide from a vial later switch to brand Zepbound pens once they meet their annual insurance deductible (typically around mid-year). The convenience of the pen outweighs the cost difference once the copay drops below CAD $75. The reverse switch (pen to vial) happens when patients lose insurance coverage, change jobs, or hit lifetime maximums on specialty drug benefits.

These patterns suggest that the optimal strategy for many Canadian patients is hybrid: use compounded tirzepatide during high-deductible months (January through April), then switch to brand Zepbound once the deductible is met and copays drop.

The decision tree: which option makes sense for your situation

Start here: Do you have private insurance that covers Zepbound?

Yes → Request prior authorization from your provider.

• PA approved → Check your copay.
• Copay under CAD $100 → Use brand Zepbound. Apply for Lilly copay card to reduce to CAD $25 if eligible.
• Copay over CAD $100 → Compare against compounded tirzepatide (CAD $245-380). If compounded is cheaper, consider switching. If copay is close, brand may be worth the convenience.
• PA denied → Appeal with additional documentation (comorbidities, prior weight-loss attempts). If appeal fails, move to compounded tirzepatide or pay retail.

No → Do you qualify for the Lilly Patient Assistance Program (income under CAD $60k individual / $90k family)?

• Yes → Apply for PAP. If approved, you get free Zepbound for 12 months.
• No → Compare retail Zepbound (CAD $395-450 + dispensing) vs compounded tirzepatide (CAD $245-380 all-in). Compounded is cheaper for most patients without coverage.

Special case: You have type 2 diabetes. Ask your provider to prescribe Mounjaro (tirzepatide for diabetes) instead of Zepbound. Mounjaro is covered by most provincial public plans and private plans with prior authorization. Same active ingredient, different indication, much better coverage.

How to verify your exact cost in under 10 minutes

Step 1: Check your insurance formulary. Log into your insurance provider's online portal (Manulife, Sun Life, Canada Life, Blue Cross, etc.). Search the drug formulary for "Zepbound" or "tirzepatide." Note the tier and whether prior authorization is required. If it's not listed, your plan doesn't cover it.

Step 2: Call your pharmacy benefits line. The phone number is on the back of your insurance card. Ask: "Does my plan cover Zepbound? What's my copay if prior authorization is approved?" The representative can run a test claim and give you an exact copay estimate.

Step 3: Get a retail quote. Call your local pharmacy (Shoppers, Rexall, Costco, etc.). Ask for the cash price of Zepbound 2.5 mg (or your prescribed dose) plus dispensing fee. This is your fallback cost if insurance doesn't cover it.

Step 4: Check Lilly copay card eligibility. Visit LillyConnect.ca. Complete the eligibility quiz. If you have private insurance that covers Zepbound, you likely qualify for the copay card (reducing copay to CAD $25).

Step 5: Compare against compounded alternatives. Check current pricing for U.S. compounded tirzepatide platforms that ship to Canada. Factor in shipping costs and currency conversion. Compare total monthly cost against your insurance copay or retail price.

This five-step process gives you three numbers: (1) your insurance copay, (2) your retail fallback cost, and (3) your compounded alternative cost. The lowest of the three is your optimal choice.

FAQ

How much does Zepbound cost in Canada without insurance? CAD $395 to $450 per month depending on dose, plus CAD $8 to $15 dispensing fee. Total out-of-pocket ranges from CAD $403 to $465 monthly at most Canadian pharmacies.

Do any Canadian provinces cover Zepbound? No. As of April 2026, zero provincial public drug plans cover Zepbound for weight management. Some provinces cover Mounjaro (same drug, diabetes indication) with prior authorization.

How much does Zepbound cost with private insurance in Canada? Typically CAD $0 to $150 per month if your plan covers it and prior authorization is approved. About 32% of employer plans cover Zepbound. Copays depend on your plan's tier structure and coinsurance percentage.

Can I use the Eli Lilly savings card in Canada? Yes, if you have private insurance that covers Zepbound. The LillyConnect copay card reduces your copay to as low as CAD $25 per fill. It doesn't work if you have no insurance or only public provincial coverage.

Is Zepbound cheaper in Canada than the U.S.? The retail list price is lower (CAD $395 vs USD $1,060), but U.S. patients with insurance or manufacturer copay assistance often pay less out-of-pocket than uninsured Canadian patients. U.S. compounded tirzepatide (USD $179-279) is often cheaper than Canadian retail Zepbound.

Can U.S. patients buy Zepbound from Canada? Not legally. The FDA prohibits personal importation of medications that are available in the U.S. under the same brand name. Zepbound is FDA-approved and sold in the U.S., making Canadian importation illegal under current policy.

Does Costco Canada have cheaper Zepbound prices? The drug cost is the same (CAD $395-450), but Costco's dispensing fee is CAD $4.49 compared to CAD $11-12 at other chains. Over 12 months, Costco saves about CAD $90 in dispensing fees. Membership required.

How do I get prior authorization for Zepbound in Canada? Your doctor submits a PA request to your insurance company with your BMI, comorbidity documentation, and records of prior weight-loss attempts. Approval typically takes 5 to 10 business days. Approval rates vary by insurer (54% to 68% on first submission).

What's the difference between Zepbound and Mounjaro in Canada? Same active ingredient (tirzepatide), different approved indications. Mounjaro is approved for type 2 diabetes and covered by most provincial plans. Zepbound is approved for weight management and not covered by public plans. If you have diabetes, Mounjaro is the better coverage option.

Can I get free Zepbound in Canada? Yes, if you qualify for the Eli Lilly Patient Assistance Program (income under CAD $60k individual or CAD $90k family, no insurance coverage). The program provides free Zepbound for 12 months, renewable annually.

Is compounded tirzepatide legal to import to Canada? Personal importation of up to a 90-day supply for personal use is permitted under Health Canada policy. Compounded tirzepatide is not Health Canada-approved, but enforcement against personal-use importation is rare. Commercial importation is prohibited.

Which Canadian pharmacy has the lowest Zepbound price? All major pharmacies charge the same drug cost (CAD $395-450) because it's set by Eli Lilly Canada. The difference is dispensing fees: Costco charges CAD $4.49, Shoppers charges CAD $11.99, Rexall charges CAD $11.50.

Sources

1. Lexchin J, et al. Patented drug prices in Canada compared to the United States: an analysis of PMPRB pricing. Health Policy. 2024.
2. RAMQ (Régie de l'assurance maladie du Québec). Liste des médicaments 2026. Gouvernement du Québec. 2026.
3. Canadian Life and Health Insurance Association. Extended health benefits coverage survey 2025. CLHIA. 2025.
4. Conference Board of Canada. Obesity treatment access and insurance coverage in Canada. 2025.
5. Ontario Drug Benefit Formulary. Comparative Drug Index. Ontario Ministry of Health. 2026.
6. British Columbia PharmaCare Formulary. BC Ministry of Health. 2026.
7. FDA. Personal importation policy: guidance for industry. U.S. Food and Drug Administration. 2024.
8. Health Canada. Personal importation of health products: guidance document. Government of Canada. 2024.
9. Lilly Canada. LillyConnect annual access report: patient support programs 2025. Eli Lilly Canada Inc. 2025.
10. Canadian Obesity Network. Provider survey: GLP-1 agonist prescribing patterns and patient assistance program utilization. 2025.
11. University of Toronto Centre for Health Economics. Cross-border pharmaceutical utilization among Canadian patients: a 2025 analysis. 2025.
12. Alberta Blue Cross. Drug benefit list 2026. Alberta Blue Cross. 2026.
13. Nova Scotia Pharmacare Formulary. Nova Scotia Department of Health and Wellness. 2026.
14. Manitoba Pharmacare Formulary. Manitoba Health, Seniors and Active Living. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Shoppers Drug Mart, Rexall, Costco, and Walmart are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.